Svjetlana Mohrmann

Multicenter phase II study of oral capecitabine (Xeloda“) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy

Peter Reichardt, Gϋnter von Minckwitz, Peter Thuss‐Patience et al. · Annals of Oncology · 2003 · 236 citations · Full text

Metastatic Breast Cancer, Oncology, Breast Oncology +7

Diagnostic leukapheresis enables reliable detection of circulating tumor cells of nonmetastatic cancer patients

Johannes Fischer, Dieter Niederacher, Stefan A. Topp et al. · Proceedings of the National Academy of Sciences · 2013 · 221 citations · Full text

Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: results of a multicentre phase III trial

Ulrike Nitz, Svjetlana Mohrmann, Johannes Fischer et al. · The Lancet · 2005 · 110 citations

Dose-dense Conventional Chemotherapy, Oncology, High-risk Breast Cancer +6

Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial

Oleg Gluz, Ulrike Nitz, Nadia Harbeck et al. · Annals of Oncology · 2008 · 102 citations

Breast Oncology, Oncology, Adjuvant Chemotherapy +6

Treatment and outcomes of patients in the Brain Metastases in Breast Cancer Network Registry

Isabell Witzel, Elena Laakmann, Rudolf Weide et al. · European Journal of Cancer · 2018 · 93 citations · Full text